Cargando…

Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment

BACKGROUND: Despite the widespread availability of naloxone, US opioid overdose rates continue to rise. The “Cascade of Care” (CoC) is a public health approach that identifies steps in achieving specific outcomes and has been used to identify gaps in naloxone carriage among individuals with opioid u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kozak, Zofia, Ciccarone, Daniel, Thrul, Johannes, Cole, Thomas O., Pappas, Alexander L., Greenblatt, Aaron D., Welsh, Christopher, Yoon, Mark, Gann, Donald, Artigiani, E. Erin, Wish, Eric D., Belcher, Annabelle M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928141/ https://www.ncbi.nlm.nih.gov/pubmed/36788601 http://dx.doi.org/10.1186/s12954-023-00745-6

Ejemplares similares

Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment
por: Belcher, Annabelle M, et al.
Publicado: (2019)

Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial
por: Belcher, Annabelle M., et al.
Publicado: (2023)

Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore
por: Abidogun, Tolulope M., et al.
Publicado: (2023)

Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
por: Gawronski, Kristen M, et al.
Publicado: (2014)

Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan
por: Goshgarian, Gregory, et al.
Publicado: (2022)

Harm reduction in the Heartland: public knowledge and beliefs about naloxone in Nebraska, USA
por: Schlosser, Allison, et al.
Publicado: (2022)

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

823 Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Race-based differences in drug use prior to onset of opioid use disorder
por: Deutsch-Link, Sasha, et al.
Publicado: (2023)

Safety of Naloxone in Opioid-Naïve Methadone Intoxicated Patients; a Case Series Study
por: Shakeri, Seyed Hamid Reza, et al.
Publicado: (2020)

Use of nebulized naloxone to reverse methadone overdose – A case report and review of literature
por: Sameed, Muhammad, et al.
Publicado: (2019)

Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder
por: CLIFTON, JOHN M., et al.
Publicado: (2022)

'Diversion’ of methadone or buprenorphine: 'harm’ versus 'helping’
por: Havnes, Ingrid Amalia, et al.
Publicado: (2013)

A harm reduction paradox: Comparing China's policies on needle and syringe exchange and methadone maintenance
por: Smith, Kumi, et al.
Publicado: (2012)

Comparing Two Naloxone Tapering Methods in Management of Methadone Intoxication; a Quasi-experimental Study
por: Zarei, Mohammad Javad, et al.
Publicado: (2023)

“Sometimes you have to take the person and show them how”: adapting behavioral activation for peer recovery specialist-delivery to improve methadone treatment retention
por: Kleinman, Mary B., et al.
Publicado: (2023)

Descriptive Aspects of Injection Drug Users in Iran’s National Harm Reduction Program by Methadone Maintenance Treatment
por: ESKANDARIEH, Sharareh, et al.
Publicado: (2013)

The Effect of Methadone Maintenance Therapy on Harm Reduction in Opiate Dependents in Kerman Socio-Behavioral Consulting Centers
por: Parvaresh, Noshin, et al.
Publicado: (2010)

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report
por: Menard, Shannon, et al.
Publicado: (2021)

Notes from the Field: High Prevalence of Fentanyl Detected by the Maryland Emergency Department Drug Surveillance System — Baltimore, Maryland, 2019
por: Dezman, Zachary, et al.
Publicado: (2020)

Harm reduction, methadone maintenance treatment and the root causes of health and social inequities: An intersectional lens in the Canadian context
por: Smye, Victoria, et al.
Publicado: (2011)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes”
por: Newman, Robert G., et al.
Publicado: (2013)

Community Case Study of Naloxone Distribution by Hospital-Based Harm Reduction Program for People Who Use Drugs in New York City
por: Riazi, Farah, et al.
Publicado: (2021)

Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
por: Bastien, Gabriel, et al.
Publicado: (2022)

Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls
por: Rapeli, Pekka, et al.
Publicado: (2007)

Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations
por: Welsh, Christopher, et al.
Publicado: (2022)

Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study
por: Bennett, Alex S, et al.
Publicado: (2020)

Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment
por: Cole, Thomas O., et al.
Publicado: (2021)

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
por: Scott, Travis M., et al.
Publicado: (2021)

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
por: Sadek, Joseph, et al.
Publicado: (2022)

Naloxone Audit
por: Venan, Paster
Publicado: (2023)

Overdue for an Overhaul: How Opioid Treatment Programs Can Learn From COVID-19
por: Greenblatt, Aaron D., et al.
Publicado: (2020)

Toward precision prescribing for methadone: Determinants of methadone deposition
por: Talal, Andrew H., et al.
Publicado: (2020)

Malmö Treatment Referral and Intervention Study—High 12-Month Retention Rates in Patients Referred from Syringe Exchange to Methadone or Buprenorphine/Naloxone Treatment
por: Bråbäck, Martin, et al.
Publicado: (2017)

Traditional Chinese medicine-facilitated treatments may relieve anxiety symptoms during drug switching from methadone to buprenorphine/naloxone for treating opioid dependence
por: Yu, Kai-Chiang, et al.
Publicado: (2017)

Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada
por: Piske, Micah, et al.
Publicado: (2020)

Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
por: Ellerbroek, Hannah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gmr25lqnn8lovnaeputbbv26qf